Table 4 Visual Outcomes at 12 Months.
From: Impact of veriflex and ICL on corneal biomechanics and endothelial cell density
Parameter | Veriflex (n = 58 eyes) | ICL (n = 59 eyes) | p-value | Interpretation |
|---|---|---|---|---|
Uncorrected Distance Visual Acuity (UDVA) | ||||
UDVA ≥ 20/25 (%) | 83% | 89% | 0.241 | No significant difference |
UDVA ≥ 20/20 (%) | 39% | 49% | 0.218 | Slight trend favoring ICL |
Best-Corrected Visual Acuity (BCVA) | ||||
Gained ≥ 2 lines (%) | 14% | 18% | 0.532 | No significant difference |
Lost 1 line (%) | 5.2% | 2.5% | 0.413 | Not significant |
Predictability (Refractive Accuracy) | ||||
SE within ± 0.50 D (%) | 66% | 76% | 0.207 | Trend favoring ICL |
SE within ± 1.00 D (%) | 89% | 95% | 0.176 | High predictability in both groups |
Stability (SE Change over 12 months) | ||||
SE mean change (6 to 12 mo) | + 0.2 ± 0.3 D | −0.3 ± 0.2 D | < 0.001 ★ | Significant hyperopic shift in Veriflex |
Endothelial Cell Count (ECC) | ||||
ECC loss at 12 months (%) | −5.43% | −1.54% | 0.021 ★ | Significantly more ECC loss in Veriflex |
